{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:27:36Z","timestamp":1792524456989,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.drugalcdep.2017.05.014","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T10:02:55Z","timestamp":1498039375000},"page":"223-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Prescribing of benzodiazepines and opioids to individuals with substance use disorders"],"prefix":"10.1016","volume":"178","author":[{"given":"Peggy L.","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy H.","family":"Karnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjushu","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.S.","family":"Kenneth Pack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Campopiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Zur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0005","first-page":"2227","article-title":"Beers criteria update expert panel, 2015. American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults","volume":"63","author":"American Geriatrics Society","year":"2015","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0010","series-title":"Practice Guideline for the Treatment of Patients with Substance Use Disorders","author":"American Psychiatric Association, Work Group on Substance Use Disorders","year":"2010"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0015","series-title":"Benzodiazepines: How Do They Work and How to Withdraw (The Ashton Manual) Institute of Neuroscience","author":"Ashton","year":"2002"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0020","series-title":"Drug-poisoning Deaths Involving Opioid Analgesics: United States, 1999\u20132011 (NCHS Data Brief 166)","author":"Chen","year":"2014"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0025","series-title":"Tranxene* T-TAB","author":"U.S. Food and Drug Administration","year":"2010"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0030","series-title":"XANAX","author":"U.S. Food and Drug Administration","year":"2011"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0035","series-title":"VALIUM","author":"U.S. Food and Drug Administration","year":"2013"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0040","unstructured":"U.S. Food and Drug Administration, n.d. Drugs@FDA: FDA Approved Drug Products (accessed 05.02.16) http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm. U.S. Food and Drug Administration, n.d. Drugs@FDA: FDA Approved Drug Products (Accessed 05.02.2016) http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm."},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0045","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.drugalcdep.2013.04.005","article-title":"Enhancing access and retention in substance abuse treatment: the role of Medicaid payment acceptance and cultural competence","volume":"132","author":"Guerrero","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/bcp.12023","article-title":"Benzodiazepine dependence and its treatment with low dose flumazenil","volume":"77","author":"Hood","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: a review of opioid and benzodiazepine combination use","volume":"125","author":"Jones","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0060","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.addbeh.2016.08.020","article-title":"Anxiety sensitivity and nonmedical benzodiazepine use among adults with opioid use disorder","volume":"65","author":"McHugh","year":"2016","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0065","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1176\/appi.ps.52.5.597","article-title":"Developing standards of care for individuals with co-occurring psychiatric and substance use disorders","volume":"52","author":"Minkoff","year":"2001","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0070","series-title":"Treating Comorbid Psychiatric and Substance Use Disorders","author":"Minkoff","year":"2013"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0075","series-title":"Overdose Death Rates","author":"National Institute on Drug Abuse","year":"2015"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0080","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3109\/10826080903442836","article-title":"Treatment guidelines for substance use disorders and serious mental illnesses: do they address co-occurring disorders?","volume":"45","author":"Perron","year":"2010","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0085","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.genhosppsych.2015.06.004","article-title":"Demographic and clinical factors associated with benzodiazepine prescription at discharge from psychiatric inpatient treatment","volume":"37","author":"Peters","year":"2015","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0090","series-title":"Benzodiazepine Abuse Treatment Admissions Have Tripled from 1998 to 2008","author":"Substance Abuse and Mental Health Services Administration","year":"2011"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0095","series-title":"The TEDS Report: Admissions Reporting Benzodiazepine and Narcotic Pain Reliever Abuse at Treatment Entry","author":"Substance Abuse and Mental Health Services Administration","year":"2012"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0100","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health","author":"Substance Abuse and Mental Health Services Administration","year":"2016"},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2016.06.008","article-title":"Reasons for benzodiazepine use among persons seeking opioid detoxification","volume":"68","author":"Stein","year":"2016","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2017.05.014_bib0110","first-page":"90","article-title":"Side effects of treatment with benzodiazepines","volume":"22","author":"Uzun","year":"2010","journal-title":"Psychiatr. Danub."},{"issue":"1007","key":"10.1016\/j.drugalcdep.2017.05.014_bib0115","first-page":"1112","article-title":"Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment","volume":"62","author":"Wisdom","year":"2011","journal-title":"Psychiatr. Serv."}],"updated-by":[{"DOI":"10.1016\/j.drugalcdep.2017.10.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000}}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617302879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617302879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T15:29:19Z","timestamp":1535729359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871617302879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":23,"alternative-id":["S0376871617302879"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.05.014","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.drugalcdep.2017.10.004","asserted-by":"object"}]},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing of benzodiazepines and opioids to individuals with substance use disorders","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}